Skip Navigation
Skip to contents

Cancer Res Treat : Cancer Research and Treatment

OPEN ACCESS

Search

Page Path
HOME > Search
15 "Ryul Kim"
Filter
Filter
Article category
Keywords
Publication year
Authors
Funded articles
Original Articles
Long-Term Survival Outcomes of Surgical Resection for Lung Adenocarcinoma with Intraoperatively Diagnosed Pleural Metastasis: Target Treatment Era
Yelee Kwon, Jae Kwang Yun, Geun Dong Lee, Se Hoon Choi, Yong-Hee Kim, Hyeong Ryul Kim
Received October 15, 2024  Accepted December 27, 2024  Published online December 30, 2024  
DOI: https://doi.org/10.4143/crt.2024.993    [Accepted]
AbstractAbstract PDF
Purpose
This study aimed to evaluate the clinical impact of main tumor resection on long-term survival compared with pleural biopsy alone in patients with lung adenocarcinoma who were intraoperatively diagnosed with pleural metastasis.
Materials and Methods
A total of 176 patients with adenocarcinoma who had unexpected pleural metastasis detected during surgery from 2002 to 2021 were retrospectively analyzed. Each surgeon decided whether to perform main tumor resection or pleural biopsy alone.
Results
The patients were grouped based on the surgical approaches: main tumor resection (Resection group; n=83) and pleural biopsy only (O&C group; n=93). The Resection group had better overall survival (OS, 10-year survival: 27.9% vs. 9.4%; median survival: 68.3 vs. 36.6 months; p<0.01) and locoregional progression-free survival (10-year survival: 12.5% vs. 7.1%; median survival: 19.6 vs. 10.6 months; p<0.01) than the O&C group. Similar results were found for OS in patients who received tyrosine kinase inhibitors (TKIs) as first-line therapy (10-year survival: 49.2% vs. 15.0%; median survival: 72.2 vs. 45.4 months; p=0.03), patients who did not undergo TKIs treatment (10-year survival: 29.4% vs. 9.2%; median survival: 82.4 vs. 23.8 months; p<0.01), and patients with positive target gene mutation (10-year survival: 31.7% vs. 10.1%; median survival: 72.2 vs. 33.7 months; p<0.01). In multivariate analysis, pleural biopsy only (hazard ratio, 1.73; p=0.04) was a significant predictor of OS.
Conclusion
Main tumor resection can improve survival in patients with lung adenocarcinoma who had unexpected pleural metastasis during operation.
  • 394 View
  • 24 Download
Close layer
General
Target-Enhanced Whole-Genome Sequencing Shows Clinical Validity Equivalent to Commercially Available Targeted Oncology Panel
Sangmoon Lee, Jin Roh, Jun Sung Park, Islam Oguz Tuncay, Wonchul Lee, Jung-Ah Kim, Brian Baek-Lok Oh, Jong-Yeon Shin, Jeong Seok Lee, Young Seok Ju, Ryul Kim, Seongyeol Park, Jaemo Koo, Hansol Park, Joonoh Lim, Erin Connolly-Strong, Tae-Hwan Kim, Yong Won Choi, Mi Sun Ahn, Hyun Woo Lee, Seokhwi Kim, Jang-Hee Kim, Minsuk Kwon
Cancer Res Treat. 2025;57(2):350-361.   Published online September 19, 2024
DOI: https://doi.org/10.4143/crt.2024.114
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
Cancer poses a significant global health challenge, demanding precise genomic testing for individualized treatment strategies. Targeted-panel sequencing (TPS) has improved personalized oncology but often lacks comprehensive coverage of crucial cancer alterations. Whole-genome sequencing (WGS) addresses this gap, offering extensive genomic testing. This study demonstrates the medical potential of WGS.
Materials and Methods
This study evaluates target-enhanced WGS (TE-WGS), a clinical-grade WGS method sequencing both cancer and matched normal tissues. Forty-nine patients with various solid cancer types underwent both TE-WGS and TruSight Oncology 500 (TSO500), one of the mainstream TPS approaches.
Results
TE-WGS detected all variants reported by TSO500 (100%, 498/498). A high correlation in variant allele fractions was observed between TE-WGS and TSO500 (r=0.978). Notably, 223 variants (44.8%) within the common set were discerned exclusively by TE-WGS in peripheral blood, suggesting their germline origin. Conversely, the remaining subset of 275 variants (55.2%) were not detected in peripheral blood using the TE-WGS, signifying them as bona fide somatic variants. Further, TE-WGS provided accurate copy number profiles, fusion genes, microsatellite instability, and homologous recombination deficiency scores, which were essential for clinical decision-making.
Conclusion
TE-WGS is a comprehensive approach in personalized oncology, matching TSO500’s key biomarker detection capabilities. It uniquely identifies germline variants and genomic instability markers, offering additional clinical actions. Its adaptability and cost-effectiveness underscore its clinical utility, making TE-WGS a valuable tool in personalized cancer treatment.
  • 1,918 View
  • 208 Download
Close layer
Lung and Thoracic cancer
Recurrence Dynamics of Pathological N2 Non–Small Cell Lung Cancer Based on IASLC Residual Tumor Descriptor
In Ha Kim, Geun Dong Lee, Sehoon Choi, Hyeong Ryul Kim, Yong-Hee Kim, Dong Kwan Kim, Seung-Il Park, Jae Kwang Yun
Cancer Res Treat. 2025;57(1):105-115.   Published online July 23, 2024
DOI: https://doi.org/10.4143/crt.2024.150
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
This study investigated the recurrence patterns and timing in patients with pathologic N2 (pN2) non-small cell lung cancer (NSCLC) according to the residual tumor (R) descriptor proposed by the International Association for the Study of Lung Cancer (IASLC).
Materials and Methods
From 2004 to 2021, patients with pN2 NSCLC who underwent anatomical resection were analyzed according to the IASLC R criteria using medical records from a single center. Survival analysis was performed using Cox proportional hazards models. Recurrence patterns between complete (R0) and uncertain resections (R[un]) were compared.
Results
In total, 1,373 patients were enrolled in this study: 576 (42.0%) in R0, 286 (20.8%) in R(un), and 511 (37.2%) in R1/R2 according to the IASLC R criteria. The most common reason for R(un) classification was positivity for the highest lymph node (88.8%). In multivariable analysis, the hazard ratios for recurrence in R(un) and R1/R2 compared to R0 were 1.18 (95% confidence interval [CI], 0.96–1.46) and 1.58 (1.31–1.90), respectively. The hazard rate curves displayed similar patterns among groups, peaking at approximately 12 months after surgery. There was a significant difference in distant recurrence patterns between R0 and R(un). Further analysis after stratification with the IASLC N2 descriptor showed significant differences in distant recurrence patterns between R0 and R(un) in patients pN2a1 and pN2a2 disease, but not in those with pN2b disease.
Conclusion
The IASLC R criteria has prognostic relevance in patients with pN2 NSCLC. R(un) is a highly heterogeneous group, and the involvement of the highest mediastinal lymph node can affect distant recurrence patterns.

Citations

Citations to this article as recorded by  
  • Evaluation of Uncertain Resection for Localized Non-small Cell Lung Cancer: The Crucial Prognosis of Suboptimal Lymph Node Assessment
    Romain Vergé, Axel Rouch, Pierre Rabinel, Claire Renaud, Mathilde Cazaux, Laurent Brouchet
    The Annals of Thoracic Surgery.2025;[Epub]     CrossRef
  • 1,324 View
  • 75 Download
  • 1 Crossref
Close layer
Differences in the Prognostic Impact between Single-Zone and Multi-Zone N2 Node Metastasis in Patients with Station-Based Multiple N2 Non–Small Cell Lung Cancer
Shia Kim, Geun Dong Lee, SeHoon Choi, Hyeong Ryul Kim, Yong-Hee Kim, Dong Kwan Kim, Seung-Il Park, Jae Kwang Yun
Cancer Res Treat. 2025;57(1):95-104.   Published online July 22, 2024
DOI: https://doi.org/10.4143/crt.2024.120
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
The International Association for the Study of Lung Cancer suggests further subdivision of pathologic N (pN) category in non–small-cell lung cancer (NSCLC) by incorporating the location and number of involved lymph node (LN) stations. We reclassified patients with the station-based N2b disease into single-zone and multi-zone N2b groups and compared survival outcomes between the groups.
Materials and Methods
This retrospective study included patients with pN2 NSCLC who underwent lobectomy from 2006 to 2019. The N2 disease was subdivided into four categories: single-station N2 without N1 (N2a1), single-station N2 with N1 (N2a2), multiple-station N2 with single zone involvement (single-zone N2b), and multiple-station N2 with multiple zone involvement (multi-zone N2b). LN zones included in the subdivision of N2 disease were upper mediastinal, lower mediastinal, aortopulmonary, and subcarinal.
Results
Among 996 eligible patients, 211 (21.2%), 394 (39.6%), and 391 (39.3%) were confirmed to have pN2a1, pN2a2, and pN2b disease, respectively. In multivariable analysis after adjustment for sex, age, pT category, and adjuvant chemotherapy, overall survival was significantly better with single-zone N2b disease (n=125, 12.6%) than with multi-zone N2b disease (n=266, 26.7%) (hazard ratio [HR], 0.67; 95% confidence interval [CI], 0.49 to 0.90; p=0.009) and was comparable to that of N2a2 disease (HR, 1.12; 95% CI, 0.83 to 1.49; p=0.46).
Conclusion
Prognosis of single-zone LN metastasis was better than that of multiple-zone LN metastasis in patients with N2b NSCLC. Along with the station-based N descriptors, zone-based descriptors might ensure optimal staging, enabling the most appropriate decision-making on adjuvant therapy for patients with pN2 NSCLC.
  • 1,585 View
  • 110 Download
Close layer
The Role of Adjuvant Therapy Following Surgical Resection of Small Cell Lung Cancer: A Multi-Center Study
Seong Yong Park, Samina Park, Geun Dong Lee, Hong Kwan Kim, Sehoon Choi, Hyeong Ryul Kim, Yong-Hee Kim, Dong Kwan Kim, Seung-Il Park, Tae Hee Hong, Yong Soo Choi, Jhingook Kim, Jong Ho Cho, Young Mog Shim, Jae Ill Zo, Kwon Joong Na, In Kyu Park, Chang Hyun Kang, Young-Tae Kim, Byung Jo Park, Chang Young Lee, Jin Gu Lee, Dae Joon Kim, Hyo Chae Paik
Cancer Res Treat. 2023;55(1):94-102.   Published online June 9, 2022
DOI: https://doi.org/10.4143/crt.2022.290
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
This multi-center, retrospective study was conducted to evaluate the long-term survival in patients who underwent surgical resection for small cell lung cancer (SCLC) and to identify the benefit of adjuvant therapy following surgery.
Materials and Methods
The data of 213 patients who underwent surgical resection for SCLC at four institutions were retrospectively reviewed. Patients who received neoadjuvant therapy or an incomplete resection were excluded.
Results
The mean patient age was 65.29±8.93 years, and 184 patients (86.4%) were male. Lobectomies and pneumonectomies were performed in 173 patients (81.2%), and 198 (93%) underwent systematic mediastinal lymph node dissections. Overall, 170 patients (79.8%) underwent adjuvant chemotherapy, 42 (19.7%) underwent radiotherapy to the mediastinum, and 23 (10.8%) underwent prophylactic cranial irradiation. The median follow-up period was 31.08 months (interquartile range, 13.79 to 64.52 months). The 5-year overall survival (OS) and disease-free survival were 53.4% and 46.9%, respectively. The 5-year OS significantly improved after adjuvant chemotherapy in all patients (57.4% vs. 40.3%, p=0.007), and the survival benefit of adjuvant chemotherapy was significant in patients with negative node pathology (70.8% vs. 39.7%, p=0.004). Adjuvant radiotherapy did not affect the 5-year OS (54.6% vs. 48.5%, p=0.458). Age (hazard ratio [HR], 1.032; p=0.017), node metastasis (HR, 2.190; p < 0.001), and adjuvant chemotherapy (HR, 0.558; p=0.019) were associated with OS.
Conclusion
Adjuvant chemotherapy after surgical resection in patients with SCLC improved the OS, though adjuvant radiotherapy to the mediastinum did not improve the survival or decrease the locoregional recurrence rate.

Citations

Citations to this article as recorded by  
  • Application of postoperative adjuvant radiotherapy in limited-stage small cell lung cancer: A systematic review and meta-analysis
    Chuanhao Zhang, Genghao Zhao, Huajian Wu, Jianing Jiang, Wenyue Duan, Zhijun Fan, Zhe Wang, Ruoyu Wang
    Radiotherapy and Oncology.2024; 193: 110123.     CrossRef
  • A 15-Gene-Based Risk Signature for Predicting Overall Survival in SCLC Patients Who Have Undergone Surgical Resection
    Sevcan Atay
    Cancers.2023; 15(21): 5219.     CrossRef
  • 6,120 View
  • 145 Download
  • 2 Web of Science
  • 2 Crossref
Close layer
Gastrointestinal cancer
Role of Esophagectomy after Chemoradiation Therapy in Patients with Locally Advanced Squamous Cell Carcinoma: A Comparative Analysis Stratified by Clinical Response to Chemoradiation Therapy
Jesang Yu, Jong Hoon Kim, Sung-Bae Kim, Sook Ryun Park, Young-Hee Kim, Hyeong Ryul Kim, Hyun Joo Lee, Ho June Song, Kye Jin Song, Jeong Yun Jang, Yoon Young Jo, Ye Jin Yoo
Cancer Res Treat. 2022;54(4):1148-1156.   Published online December 20, 2021
DOI: https://doi.org/10.4143/crt.2021.885
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
This study aimed to evaluate the long-term effect of esophagectomy in patients with esophageal squamous cell carcinoma (ESCC) by comparing the chemoradiotherapy (CRT)-only group and the trimodality treatment (TMT) group who received concurrent CRT followed by surgery.
Materials and Methods
We included 412 operable ESCC patients treated with TMT or CRT between January 2005 and December 2015. The oncological outcomes of the two groups were compared using a weighted Cox proportional-hazards model with inverse probability of treatment weighting (IPTW).
Results
The median survival time was 64 and 32 months in the TMT (n=270) and CRT (n=142) groups, respectively (p < 0.001). After IPTW, the median overall survival (OS) remained significantly higher in the TMT group than in the CRT group (61 months vs. 32 months, p=0.016). Moreover, the TMT group showed a better local recurrence-free rate (LRFR, p < 0.001) and distant metastasis-free rate (p=0.007). In the subgroup of patients with clinical complete response (cCR), the OS was not significantly different between the two groups, both before and after IPTW adjustment (p=0.35 and p=0.93). However, among non-cCR patients, the OS was significantly higher in the TMT group (64% vs. 45%, p < 0.001).
Conclusion
In patients with locally advanced ESCC, TMT was superior to CRT in terms of OS and LRFR. Such difference was more prominent in the non-cCR subgroup. In patients who achieved cCR, esophagectomy was effective in improving LRFR but not OS, suggesting that esophagectomy may be omitted in complete responders.

Citations

Citations to this article as recorded by  
  • Diagnosing Complete Response to Preoperative Chemoradiation in Esophageal Cancer Using Dynamic Contrast-Enhanced MRI Response Criteria
    Yura Ahn, Jooae Choe, Hyun Joo Lee, Sook Ryun Park, Jong-Hoon Kim, Ho June Song, Min-Ju Kim, Yong-Hee Kim
    Korean Journal of Radiology.2025; 26(3): 269.     CrossRef
  • Comparison of esophageal cancer survival after neoadjuvant chemoradiotherapy plus surgery versus definitive chemoradiotherapy: A systematic review and meta-analysis
    Junli Ke, Yujie Xie, Shenyang Huang, Wei Wang, Zhengang Zhao, Wanli Lin
    Asian Journal of Surgery.2024; 47(9): 3827.     CrossRef
  • Multi-disciplinary management of esophageal carcinoma: Current practices and future directions
    Chanyoot Bandidwattanawong
    Critical Reviews in Oncology/Hematology.2024; 197: 104315.     CrossRef
  • Practice pattern and risk of not receiving planned surgery after neoadjuvant chemoradiotherapy for locally advanced oesophageal squamous cell carcinoma
    Tae Hee Hong, Tae Ho Kim, Genehee Lee, Jeonghee Yun, Yeong Jeong Jeon, Junghee Lee, Sumin Shin, Seong Yong Park, Jong Ho Cho, Yong Soo Choi, Young Mog Shim, Jong-Mu Sun, Dongryul Oh, Hong Kwan Kim
    European Journal of Cardio-Thoracic Surgery.2024;[Epub]     CrossRef
  • Induction Therapy of Tislelizumab Combined with Cisplatin and 5-Fluorouracil and Subsequent Conversion Surgery in Patients with Unresectable Advanced Esophageal Squamous Cell Carcinoma: A Phase 2, Single Center Study
    Tongpeng Xu, Jianan Bai, Kun Zhao, Xiaofeng Chen, Shuhui Wang, Shusheng Zhu, Chongqi Sun, Chenhui Zhao, Ting Wang, Ling Zhu, Meizhen Hu, Fei Pang, Junling Zhang, Wei Wang, Yongqian Shu, Fang Li, Yue Zhou
    Annals of Surgical Oncology.2024; 31(13): 9321.     CrossRef
  • Unveiling Therapeutic Targets for Esophageal Cancer: A Comprehensive Review
    Rakesh Acharya, Ananya Mahapatra, Henu Kumar Verma, L. V. K. S. Bhaskar
    Current Oncology.2023; 30(11): 9542.     CrossRef
  • Nomogram for predicting pathologic complete response following preoperative chemoradiotherapy in patients with esophageal squamous cell carcinoma
    Young Seob Shin, Jeong Yun Jang, Ye Jin Yoo, Jesang Yu, Kye Jin Song, Yoon Young Jo, Sung-Bae Kim, Sook Ryun Park, Ho June Song, Yong-Hee Kim, Hyeong Ryul Kim, Jong Hoon Kim
    Gastroenterology Report.2023;[Epub]     CrossRef
  • 6,188 View
  • 129 Download
  • 9 Web of Science
  • 7 Crossref
Close layer
Genitourinary cancer
Genomic Sequencing for Bladder Urothelial Carcinoma and Its Clinical Implications for Immunotherapy
Ryul Kim, Jung Yong Hong, Jeeyun Lee, Ghee Young Kwon, Byong Chang Jeong, Se Hoon Park
Cancer Res Treat. 2022;54(3):894-906.   Published online November 17, 2021
DOI: https://doi.org/10.4143/crt.2021.854
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
This study aimed to explore the genomic and transcriptomic landscape of bladder cancer (BC) and its implication for treatment with an immune checkpoint inhibitor (ICI).
Materials and Methods
We analyzed whole-exome and -transcriptome sequences of tumor samples from 64 BC patients who underwent surgical resection with either transurethral resection or radical cystectomy. For exploratory purposes, programmed death-ligand 1 (PD-L1) expression was evaluated in a subset of patients (n=57) including those treated with ICI (n=8).
Results
We identified frequent molecular dysregulations in chromatin regulatory genes (KDM6A, ARID1A, MLL2, and STAG2) and recurrent copy number alterations. Thirty-five samples (54.7%) were PD-L1–positive (PD-L1 combined positive score ≥ 1) with a significantly higher exonic tumor mutational burden (TMB) compared to PD-L1–negative BC samples (p=0.010). We observed that various immune-responsive pathways, including the PD-L1 signaling pathway, were enriched significantly in PD-L1–positive BCs. Interestingly, genes in the CTLA4 pathway were enriched significantly in PD-L1–positive BC as well. Among eight patients who received ICI, progressive disease was confirmed in one patient, whose tumor had low exonic TMB, negative PD-L1 status, and a relatively colder microenvironment.
Conclusion
Gaining new insights into the molecular landscape of BC will improve treatment strategies. Our analysis suggests a rationale for studying dual checkpoint inhibition against BC.

Citations

Citations to this article as recorded by  
  • Targeting the PD-1/PD-L1 Signaling Pathway for Cancer Therapy: Focus on Biomarkers
    Areti Strati, Christos Adamopoulos, Ioannis Kotsantis, Amanda Psyrri, Evi Lianidou, Athanasios G. Papavassiliou
    International Journal of Molecular Sciences.2025; 26(3): 1235.     CrossRef
  • Development of a Technique for Diagnosis and Screening of Superficial Bladder Cancer by Cell-Pellet DNA From Urine Sample
    Jaekwon Seok, Hee Jeong Kwak, Chan-Koo Kang, Ah Ram Kim, Woo Suk Choi, Hyoung Keun Park, Sung Hyun Paick, Hyeong Gon Kim, Yeonjoo Kwak, Tak-Il Jeon, Kyung Min Lim, Baeckseung Lee, Aram Kim, Ssang-Goo Cho
    Laboratory Investigation.2025; 105(6): 104124.     CrossRef
  • The role of lysine-specific demethylase 6A (KDM6A) in tumorigenesis and its therapeutic potentials in cancer therapy
    Li-Juan Chen, Xin-Yang Xu, Xiao-Dan Zhong, Yan-Jun Liu, Ming-Hui Zhu, Fan Tao, Chang-Yun Li, Qiu-Sheng She, Guan-Jun Yang, Jiong Chen
    Bioorganic Chemistry.2023; 133: 106409.     CrossRef
  • A novel cuproptosis-related lncRNAs signature predicts prognostic and immune of bladder urothelial carcinoma
    Zheng Zhou, Yusong Zhou, Wei Liu, Jing Dai
    Frontiers in Genetics.2023;[Epub]     CrossRef
  • Implication of KDM6A in Bladder Cancer
    Marianne Matar, Gilles Prince, Ibrahim Hamati, Maria Baalbaky, Jonas Fares, Marc Aoude, Charbel Matar, Hampig Raphael Kourie
    Pharmacogenomics.2023; 24(9): 509.     CrossRef
  • Subsequent Systemic Therapy following Platinum and Immune Checkpoint Inhibitors in Metastatic Urothelial Carcinoma
    Joohyun Hong, Hyun Hwan Sung, Byong Chang Jeong, Se Hoon Park
    Biomedicines.2022; 10(8): 2005.     CrossRef
  • Antineoplastics

    Reactions Weekly.2022; 1933(1): 61.     CrossRef
  • Cuproptosis-related lncRNA signatures predict prognosis and immune relevance of kidney renal papillary cell carcinoma
    Tongjin Xie, Bin Liu, Dongbo Liu, Yusong Zhou, Qingping Yang, Dai Wang, Mengjie Tang, Wei Liu
    Frontiers in Pharmacology.2022;[Epub]     CrossRef
  • 7,828 View
  • 247 Download
  • 7 Web of Science
  • 8 Crossref
Close layer
Gastrointestinal cancer
Real-World Efficacy Data and Predictive Clinical Parameters for Treatment Outcomes in Advanced Esophageal Squamous Cell Carcinoma Treated with Immune Checkpoint Inhibitors
Jwa Hoon Kim, Bokyung Ahn, Seung-Mo Hong, Hwoon-Yong Jung, Do Hoon Kim, Kee Don Choi, Ji Yong Ahn, Jeong Hoon Lee, Hee Kyoung Na, Jong Hoon Kim, Yong-Hee Kim, Hyeong Ryul Kim, Hyun Joo Lee, Sung-Bae Kim, Sook Ryun Park
Cancer Res Treat. 2022;54(2):505-516.   Published online June 23, 2021
DOI: https://doi.org/10.4143/crt.2020.1198
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
This study aimed to evaluate the real-world efficacy of immune checkpoint inhibitors (ICIs), and to identify clinicolaboratory factors to predict treatment outcomes in patients with advanced esophageal squamous cell carcinoma (ESCC) receiving ICIs.
Materials and Methods
Sixty patients with metastatic or unresectable ESCC treated with nivolumab (n=48) or pembrolizumab (n=12) as ≥ second-line treatment between 2016 and 2019 at Asan Medical Center were included.
Results
The median age of the patients was 68 years (range, 52 to 76 years), and 93.3% were male. Most patients had metastatic disease (81.7%) and had been previously treated with fluoropyrimidines, platinum, and taxane. In 53 patients with measurable disease, the overall response rate and disease control rate were 15.1% and 35.8%, respectively. With a median follow-up duration of 16.0 months, the median progression-free survival (PFS) and overall survival (OS) were 1.9 months (95% confidence interval [CI], 1.54 to 2.19) and 6.4 months (95% CI, 4.77 to 8.11), respectively. After multivariate analysis, recent use of antibiotics, low prognostic nutrition index (< 35.93), high Glasgow Prognosis Score (≥ 1) at baseline, and ≥ 1.4-fold increase in neutrophil-to-lymphocyte ratio after one cycle from baseline were significantly unfavorable factors for both PFS and OS. Younger age (< 65 years) was a significant factor for unfavorable PFS and hyponatremia (< 135 mmol/L) for unfavorable OS.
Conclusion
The use of ICIs after the failure of chemotherapy showed comparable efficacy in patients with advanced ESCC in real practice; this may be associated with host immune-nutritional status, which could be predicted by clinical and routine laboratory factors.

Citations

Citations to this article as recorded by  
  • Pretreatment neutrophil-to-lymphocyte ratio is associated with immunotherapy efficacy in patients with advanced cancer: a systematic review and meta-analysis
    Jialin Su, Yuning Li, Shuhua Tan, Tianli Cheng, Yongzhong Luo, Lemeng Zhang
    Scientific Reports.2025;[Epub]     CrossRef
  • Prognostic value of liver metastasis in patients with esophageal squamous cell carcinoma treated with nivolumab
    Ryuichi Morita, Takeshi Ishikawa, Toshifumi Doi, Junichiro Itani, Daiki Sone, Naoto Iwai, Ken Inoue, Hirotaka Konishi, Osamu Dohi, Naohisa Yoshida, Atsushi Shiozaki, Kazuhiko Uchiyama, Tomohisa Takagi, Hitoshi Fujiwara, Hideyuki Konishi, Yoshito Itoh
    Oncology Letters.2025;[Epub]     CrossRef
  • Efficacy and safety of camrelizumab combined with chemotherapy as second-line treatment for locally advanced, recurrent, or metastatic esophageal squamous cell carcinoma
    Yinfang Gu, Xiaofang Zou, Junlin Zhu, Guowu Wu
    World Journal of Surgical Oncology.2025;[Epub]     CrossRef
  • The prognostic value of pretreatment neutrophil-lymphocyte ratio and platelet-lymphocyte ratio in patients with esophageal cancer undergoing immunotherapy: a systematic review and meta-analysis
    Min Deng, Yun Qing, Dan Qiu, Ya Sheng, Juan Zhou, Lan Sun
    Frontiers in Oncology.2025;[Epub]     CrossRef
  • Effectiveness, safety, and patterns of use of camrelizumab in advanced esophageal cancer: an individual patient data pooled analysis of 987 patients from three prospective cohort studies
    Zhihao Lu, Guoping Sun, Jiancheng Li, Jun Zhao, Zishu Wang, Dong Qian, Zhe Yang, Na Li, Junsheng Wang, Shuanghu Yuan, Yusheng Wang, Suyi Li, Zhen Yang, Fengming Ran, Yinghua Ji, Shaojin Zhu, Yanqiao Zhang, Chen Wang, Lixin Wan, Rongrong Zheng, Wenjie Deng
    Cancer Immunology, Immunotherapy.2025;[Epub]     CrossRef
  • Nutritional management during chemotherapy and chemoradiotherapy for advanced esophageal cancer
    Yutaka Kimura, Atsushi Gakuhara, Shuichi Fukuda, Yasunari Fukuda, Terukazu Yoshihara, Chikato Koga, Naotsugu Haraguchi, Jin-ichi Hida
    Esophagus.2025;[Epub]     CrossRef
  • Clinical features and treatment outcomes of PD-1 inhibitor therapy in elderly patients (≥ 65 years) with advanced esophageal squamous cell carcinoma: a real-world study
    Yi Yu, Tao Wu, Wei Gan, Can Liu, Ran Zhang, Jinxiu Zheng, Jianping Xiong, Jun Chen, Junhe Li
    Clinical and Translational Oncology.2024; 26(9): 2360.     CrossRef
  • Pembrolizumab for recurrent locally advanced or metastatic squamous cell carcinoma of the esophagus: a drug safety evaluation
    Kazumasa Yamamoto, Shun Yamamoto, Ken Kato
    Expert Opinion on Drug Safety.2024; 23(6): 667.     CrossRef
  • Efficacy and survival of nivolumab treatment for recurrent/unresectable esophageal squamous-cell carcinoma: real-world clinical data from a large multi-institutional cohort
    Tomoki Makino, Shigeto Nakai, Kota Momose, Kotaro Yamashita, Koji Tanaka, Hiroshi Miyata, Sachiko Yamamoto, Masaaki Motoori, Yutaka Kimura, Yuki Ushimaru, Motohiro Hirao, Jin Matsuyama, Yusuke Akamaru, Yukinori Kurokawa, Hidetoshi Eguchi, Yuichiro Doki
    Esophagus.2024; 21(3): 319.     CrossRef
  • The impact of antibiotic use in gastrointestinal tumors treated with immune checkpoint inhibitors: systematic review and meta-analysis
    Faizah M. Alotaibi, Ibrahim Abdullah S. Albalawi, Amna M. Anis, Hawazin Alotaibi, Seham Khashwayn, Kanan Alshammari, Jaffar A. Al-Tawfiq
    Frontiers in Medicine.2024;[Epub]     CrossRef
  • Prognostic factors of second-line nivolumab monotherapy for unresectable or metastatic esophageal cancer: a multi-institutional cohort study for 184 cases
    Sho Sato, Takashi Suzuki, Takashi Chinen, Hironori Yamaguchi, Yusuke Suzuki, Nobukazu Hokamura, Zenichiro Saze, Koji Kono, Keita Takahashi, Fumiaki Yano, Tsutomu Sato, Takashi Kosaka, Itaru Endo, Yasushi Ichikawa, Yutaka Miyawaki, Hiroshi Sato, Hideaki Sh
    Journal of Gastroenterology.2024; 59(11): 979.     CrossRef
  • Prognostic biomarkers for immunotherapy in esophageal cancer
    Xu Tong, Meiyuan Jin, Lulu Wang, Dongli Zhang, Yuping Yin, Qian Shen
    Frontiers in Immunology.2024;[Epub]     CrossRef
  • Prognostic nutritional index as a prognostic biomarker for gastrointestinal cancer patients treated with immune checkpoint inhibitors
    Lilong Zhang, Wangbin Ma, Zhendong Qiu, Tianrui Kuang, Kunpeng Wang, Baohong Hu, Weixing Wang
    Frontiers in Immunology.2023;[Epub]     CrossRef
  • Impact of Patient Characteristics on the Outcomes of Patients with Gastrointestinal Cancers Treated with Immune Checkpoint Inhibitors
    Hyejee Ohm, Omar Abdel-Rahman
    Current Oncology.2023; 30(1): 786.     CrossRef
  • A systematic review and meta-analysis evaluating the impact of antibiotic use on the clinical outcomes of cancer patients treated with immune checkpoint inhibitors
    Athéna Crespin, Clément Le Bescop, Jean de Gunzburg, Fabien Vitry, Gérard Zalcman, Julie Cervesi, Pierre-Alain Bandinelli
    Frontiers in Oncology.2023;[Epub]     CrossRef
  • The Use of Antibiotics During Immune Checkpoint Inhibitor Treatment Is Associated with Lower Survival in Advanced Esophagogastric Cancer
    Lilong Zhang, Tianrui Kuang, Dongqi Chai, Wenhong Deng, Peng Wang, Weixing Wang
    International Immunopharmacology.2023; 119: 110200.     CrossRef
  • Predictive Impact of Prognostic Nutritional Index in Patients with Cancer Treated with Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis
    Xin-Tian Xu, Yu Qian, Meng-Xing Tian, Chen-Chen Ding, Huan Guo, Jing Tang, Guo-Liang Pi, Yuan Wu, Zhu Dai, Xin Jin
    Nutrition and Cancer.2023; 75(6): 1413.     CrossRef
  • Immune checkpoint inhibitors in the treatment of oesophageal squamous cell carcinoma: where are we and where are we going?
    Ning Chen, Xiaoling Xu, Yun Fan
    Therapeutic Advances in Medical Oncology.2023;[Epub]     CrossRef
  • 進行食道癌に対する化学療法,化学放射線療法における栄養管理
    豊 木村
    The Japanese Journal of SURGICAL METABOLISM and NUTRITION.2023; 57(6): 183.     CrossRef
  • Prognostic and predictive impact of neutrophil‐to‐lymphocyte ratio and HLA‐I genotyping in advanced esophageal squamous cell carcinoma patients receiving immune checkpoint inhibitor monotherapy
    Lin Wang, Yanrong Zhu, Bo Zhang, Xi Wang, Hongnan Mo, Yuchen Jiao, Jiachen Xu, Jing Huang
    Thoracic Cancer.2022; 13(11): 1631.     CrossRef
  • Prognostic Nutritional Index Predicts Response and Prognosis in Cancer Patients Treated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis
    Liwei Ni, Jing Huang, Jiyuan Ding, Junyan Kou, Tingting Shao, Jun Li, Liujie Gao, Wanzhen Zheng, Zhen Wu
    Frontiers in Nutrition.2022;[Epub]     CrossRef
  • The impact of antibiotic use on clinical features and survival outcomes of cancer patients treated with immune checkpoint inhibitors
    Jiaxin Zhou, Guowei Huang, Wan-Ching Wong, Da-hai Hu, Jie-wen Zhu, Ruiman Li, Hong Zhou
    Frontiers in Immunology.2022;[Epub]     CrossRef
  • The prognostic value of prognostic nutritional index in advanced cancer receiving PD‐1/L1 inhibitors: A meta‐analysis
    Pengfei Li, Yutian Lai, Long Tian, Qinghua Zhou
    Cancer Medicine.2022; 11(16): 3048.     CrossRef
  • Intratumoral immunotherapy using a TLR2/3 agonist, L-pampo, induces robust antitumor immune responses and enhances immune checkpoint blockade
    Won Suk Lee, Dong Sung Kim, Jeong Hun Kim, Yoonki Heo, Hannah Yang, Eun-Jin Go, Jin Hyoung Kim, Seung Joon Lee, Byung Cheol Ahn, Jung Sun Yum, Hong Jae Chon, Chan Kim
    Journal for ImmunoTherapy of Cancer.2022; 10(6): e004799.     CrossRef
  • Focus on the Dynamics of Neutrophil-to-Lymphocyte Ratio in Cancer Patients Treated with Immune Checkpoint Inhibitors: A Meta-Analysis and Systematic Review
    Yusheng Guo, Dongqiao Xiang, Jiayu Wan, Lian Yang, Chuansheng Zheng
    Cancers.2022; 14(21): 5297.     CrossRef
  • The association between albumin levels and survival in patients treated with immune checkpoint inhibitors: A systematic review and meta-analysis
    Deniz Can Guven, Taha Koray Sahin, Enes Erul, Alessandro Rizzo, Angela Dalia Ricci, Sercan Aksoy, Suayib Yalcin
    Frontiers in Molecular Biosciences.2022;[Epub]     CrossRef
  • Nomogram Based on Monocyte-to-Lymphocyte Ratio to Predict Survival of Unresectable Esophageal Squamous Cell Carcinoma Who Receive First-Line PD-1/PD-L1 Inhibitors Combined with Chemotherapy
    Xiaolu Ma, Yongfeng Ding, Jiong Qian, Mingyu Wan, Ning Li, Chenyu Mao, Cheng Xiao, Haiping Jiang, Yulong Zheng, Luntao Wu, Xiaoyu Chen, Nong Xu
    Current Oncology.2022; 29(11): 8937.     CrossRef
  • 9,208 View
  • 309 Download
  • 27 Web of Science
  • 27 Crossref
Close layer
Lung Cancer
Prognostic Factor and Clinical Outcome in Stage III Non-Small Cell Lung Cancer: A Study Based on Real-World Clinical Data in the Korean Population
Ho Cheol Kim, Wonjun Ji, Jae Cheol Lee, Hyeong Ryul Kim, Si Yeol Song, Chang-Min Choi, Korean Association for Lung Cancer, Korea Central Cancer Registry
Cancer Res Treat. 2021;53(4):1033-1041.   Published online February 16, 2021
DOI: https://doi.org/10.4143/crt.2020.1350
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
The optimal treatment for patients with stage III non-small cell lung cancer (NSCLC) remains controversial. This study aimed to investigate prognostic factors and clinical outcome in stage III NSCLC using real-world clinical data in the Korean population.
Materials and Methods
Among 8,110 patients with lung cancer selected from 52 hospitals in Korea during 2014-2016, only patients with stage III NSCLC were recruited and analyzed. A standardized protocol was used to collect clinical information and cox proportional hazards models were used to identify risk factors for mortality.
Results
A total of 1,383 patients (46.5% had squamous cell carcinoma and 40.9% had adenocarcinoma) with stage III NSCLC were enrolled, and their median age was 70 years. Regarding clinical stage, 548 patients (39.6%) had stage IIIA, 517 (37.4%) had stage IIIB, and 318 (23.0%) had stage IIIC. Pertaining to the initial treatment method, the surgery group (median survival period: 36 months) showed better survival outcomes than the non-surgical treatment group (median survival period: 18 months, p=0.001) in patients with stage IIIA. Moreover, among patients with stage IIIB and stage IIIC, those who received concurrent chemotherapy and radiation therapy (CCRT, median survival period: 24 months) showed better survival outcomes than those who received chemotherapy (median survival period: 11 months), or radiation therapy (median survival period: 10 months, p<0.001).
Conclusion
While surgery might be feasible as the initial treatment option in patients with stage IIIA NSCLC, CCRT showed a beneficial role in patients with stage IIIB and IIIC NSCLC.

Citations

Citations to this article as recorded by  
  • The value of 18F-FDG PET/CT combined with 3D quantitative technology and clinicopathological features in predicting prognosis of NSCLC
    Yuling Su, Siwen Qiu, Jinyu Wang
    Frontiers in Oncology.2025;[Epub]     CrossRef
  • Real‐world treatment patterns and clinical outcomes in patients with stage III NSCLC in Korea: The KINDLE study
    Jiyun Lee, Hee Kyung Ahn, Sang‐We Kim, Ji‐Youn Han, Sung Sook Lee, Hyung Soon Park, Hyun Woo Lee, Joo‐Hang Kim, Eunhan Cho, Reto Huggenberger, Byoung Chul Cho
    Cancer Medicine.2024;[Epub]     CrossRef
  • Contribution of Enhanced Locoregional Control to Improved Overall Survival with Consolidative Durvalumab after Concurrent Chemoradiotherapy in Locally Advanced Non–Small Cell Lung Cancer: Insights from Real-World Data
    Jeong Yun Jang, Si Yeol Song, Young Seob Shin, Ha Un Kim, Eun Kyung Choi, Sang-We Kim, Jae Cheol Lee, Dae Ho Lee, Chang-Min Choi, Shinkyo Yoon, Su Ssan Kim
    Cancer Research and Treatment.2024; 56(3): 785.     CrossRef
  • Risk factors in depression in oncology patients. Dr. Julio Villacreses Colmont Hospital
    Mayra Viviana Zambrano Escobar, Julia Teresa Espinel García
    Seminars in Medical Writing and Education.2024; 3: 660.     CrossRef
  • Glucose metabolic heterogeneity correlates with pathological features and improves survival stratification of resectable lung adenocarcinoma
    Yu-Hung Chen, Yen-Chang Chen, Kun-Han Lue, Sung-Chao Chu, Bee-Song Chang, Ling-Yi Wang, Ming-Hsun Li, Chih-Bin Lin
    Annals of Nuclear Medicine.2023; 37(2): 139.     CrossRef
  • The combined tumor-nodal glycolytic entropy improves survival stratification in nonsmall cell lung cancer with locoregional disease
    Yu-Hung Chen, Kun-Han Lue, Sung-Chao Chu, Bee-Song Chang, Chih-Bin Lin
    Nuclear Medicine Communications.2023; 44(1): 100.     CrossRef
  • Prognostic value of pretherapeutic FDG PET/CT in non-small cell lung cancer with pulmonary lymphangitic carcinomatosis
    Yong-Jin Park, Yunjoo Im, O. Jung Kwon, Joungho Han, Myung-Ju Ahn, Jhingook Kim, Sang-Won Um, Joon Young Choi
    Scientific Reports.2023;[Epub]     CrossRef
  • A Propensity-Matched Retrospective Comparative Study with Historical Control to Determine the Real-World Effectiveness of Durvalumab after Concurrent Chemoradiotherapy in Unresectable Stage III Non-Small Cell Lung Cancer
    Cheol-Kyu Park, Nakyung Jeon, Hwa-Kyung Park, Hyung-Joo Oh, Young-Chul Kim, Ha-Lim Jeon, Yong-Hyub Kim, Sung-Ja Ahn, In-Jae Oh
    Cancers.2023; 15(5): 1606.     CrossRef
  • Association between clinical outcomes and local treatment in stage IV non‐small cell lung cancer patients with single extrathoracic metastasis
    Jeong Uk Lim, Hye Seon Kang, Ah Young Shin, Chang Dong Yeo, Chan Kwon Park, Sang Haak Lee, Seung Joon Kim
    Thoracic Cancer.2022; 13(9): 1349.     CrossRef
  • Conversion therapy from unresectable stage IIIC non-small-cell lung cancer to radical surgery via anti-PD-1 immunotherapy combined with chemotherapy and anti-angiogenesis: A case report and literature review
    Guohua Jia, Shuimei Zhou, Tangpeng Xu, Yabing Huang, Xiangpan Li
    Frontiers in Oncology.2022;[Epub]     CrossRef
  • A phase II, multicenter study of lazertinib as consolidation therapy in patients with locally advanced, unresectable, EGFR mutation‐positive non‐small cell lung cancer (stage III) who have not progressed following definitive, platinum‐based, chemoradiatio
    Juwhan Choi, Jeong Eun Lee, Chang‐Min Choi, In‐Jae Oh, Kye Young Lee, Tae Won Jang, Seung Hyeun Lee, Eun Young Kim, Dong Won Park, Sun Hyo Park, Sung Yong Lee
    Thoracic Cancer.2022; 13(23): 3431.     CrossRef
  • Prognostic Value of Combing Primary Tumor and Nodal Glycolytic–Volumetric Parameters of 18F-FDG PET in Patients with Non-Small Cell Lung Cancer and Regional Lymph Node Metastasis
    Yu-Hung Chen, Sung-Chao Chu, Ling-Yi Wang, Tso-Fu Wang, Kun-Han Lue, Chih-Bin Lin, Bee-Song Chang, Dai-Wei Liu, Shu-Hsin Liu, Sheng-Chieh Chan
    Diagnostics.2021; 11(6): 1065.     CrossRef
  • 8,424 View
  • 226 Download
  • 12 Web of Science
  • 12 Crossref
Close layer
The Effect of Induction Chemotherapy Using Docetaxel, Cisplatin, and Fluorouracil on Survival in Locally Advanced Head and Neck Squamous Cell Carcinoma: A Meta-Analysis
Ryul Kim, Seokyung Hahn, Junghoon Shin, Chan-Young Ock, Miso Kim, Bhumsuk Keam, Tae Min Kim, Dong-Wan Kim, Dae Seog Heo
Cancer Res Treat. 2016;48(3):907-916.   Published online November 17, 2015
DOI: https://doi.org/10.4143/crt.2015.359
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
The purpose of this study was to compare the survival of patients with locally advanced head and neck squamous cell carcinoma (LA-HNSCC) undergoing concurrent chemoradiotherapy (CRT) alone with that of patients undergoing induction chemotherapy (IC) using docetaxel, cisplatin, and 5-fluorouracil (TPF) followed by CRT.
Materials and Methods
A search of the PubMed, EMBASE, and Cochrane Library databases was performed in April 2015 and abstracts from the American Society of Clinical Oncology meetings (2008-2014) were reviewed. Summaries of the results were pooled using a fixed-effect model, and the risk of bias was evaluated using the Cochrane tool.
Results
A total of six relevant trials comprising 1,280 patients were identified. There was no statistically significant overall survival (OS) advantage for TPF prior to CRT (TPF/CRT) over CRT alone (hazard ratio [HR] 0.92; 95% confidence interval [CI], 0.79 to 1.09; p=0.339). Progression- free survival (PFS) was significantly longer in the TPF/CRT arms (HR, 0.82; 95% CI, 0.70 to 0.95; p=0.009). Patients with non-oropharyngeal LA-HNSCC obtained the greatest OS and PFS benefits from TPF (HR, 0.68; 95% CI, 0.47 to 0.99; p=0.043 and HR, 0.67; 95% CI, 0.48 to 0.94; p=0.022, respectively). The complete response rate was significantly increased (risk ratio [RR], 1.34; 95% CI, 1.14 to 1.56; p < 0.001), and the distant metastasis rate tended to decrease (RR, 0.65; 95% CI, 0.40 to 1.04; p=0.071) in the TPF/CRT arms.
Conclusion
IC with TPF followed by CRT is not superior to CRT alone for OS. However, PFS and the complete response rate were significantly improved in the TPF/CRT arms. TPF/CRT for patients with nonoropharyngeal LA-HNSCC provided clear survival advantages.

Citations

Citations to this article as recorded by  
  • Role of induction chemotherapy for locally advanced oral squamous cell carcinoma. A systematic review and meta-analysis based on the GRADE approach
    Saisei Fu, Haruki Sato, Mitsuo Goto, Saki Tanno, Daisuke Takeda, Taiki Suzuki, Hidemichi Yuasa, Masatoshi Adachi, Narikazu Uzawa, Hiroshi Kurita
    Journal of Oral and Maxillofacial Surgery, Medicine, and Pathology.2024; 36(3): 278.     CrossRef
  • Clinical decision pathway and management of locally advanced head and neck squamous cell carcinoma: A multidisciplinary consensus in Asia-Pacific
    Ye Guo, Torahiko Nakashima, Byoung Chul Cho, Darren W.-T. Lim, Muh-Hwa Yang, Pei-Jen Lou, June Corry, Jin Ching Lin, Guo Pei Zhu, Kyung Hwan Kim, Bin Zhang, Zhiming Li, Ruey-Long Hong, Junice Yi Siu Ng, Ee Min Tan, Yan Ping Liu, Con Stylianou, Carmel Spit
    Oral Oncology.2024; 148: 106657.     CrossRef
  • International Consensus Statement on Allergy and Rhinology: Sinonasal Tumors
    Edward C. Kuan, Eric W. Wang, Nithin D. Adappa, Daniel M. Beswick, Nyall R. London, Shirley Y. Su, Marilene B. Wang, Waleed M. Abuzeid, Borislav Alexiev, Jeremiah A. Alt, Paolo Antognoni, Michelle Alonso‐Basanta, Pete S. Batra, Mihir Bhayani, Diana Bell,
    International Forum of Allergy & Rhinology.2024; 14(2): 149.     CrossRef
  • Indian clinical practice consensus guidelines for the management of oropharyngeal cancer: Update 2022
    Vanita Noronha, Kumar Prabhash, K Govind Babu, Pankaj Chaturvedi, Moni Kuriakose, Praveen Birur, Anil K Anand, Ashish Kaushal, Abhishek Mahajan, Judita Syiemlieh, Manish Singhal, Munish Gairola, Prakash Ramachandra, Sumit Goyal, Subashini John, Rohit Nayy
    Cancer Research, Statistics, and Treatment.2024; 7(Suppl 1): S12.     CrossRef
  • Indian clinical practice consensus guidelines for the management of hypopharyngeal cancer: Update 2022
    K Govind Babu, Kumar Prabhash, Pankaj Chaturvedi, Moni Kuriakose, Praveen Birur, Anil K. Anand, Ashish Kaushal, Abhishek Mahajan, Judita Syiemlieh, Manish Singhal, Munish Gairola, Prakash Ramachandra, Sumit Goyal, Subashini John, Rohit Nayyar, Vijay M. Pa
    Cancer Research, Statistics, and Treatment.2024; 7(Suppl 1): S17.     CrossRef
  • Locally advanced and unresectable squamous cell carcinoma
    Julio José Lambea Sorrosal, María Zapata García, Alba Moratiel Pellitero, Karla Andrea Osorio Macassi, Isabel Pajares Bernad, Inés Ruiz Moreno, Sara Esteras Per
    Revisiones en Cáncer.2024;[Epub]     CrossRef
  • Role of induction chemotherapy in advanced‐stage olfactory neuroblastoma
    Sung‐Woo Cho, Bhumsuk Keam, Keun‐Wook Lee, Ji‐Won Kim, Doo Hee Han, Hyun Jik Kim, Jeong‐Whun Kim, Dong‐Young Kim, Chae‐Seo Rhee, Yun Jung Bae, Ji‐Hoon Kim, Keun‐Yong Eom, Hong‐Gyun Wu, Yong Hwy Kim, Chae‐Yong Kim, Sun Ha Paek, Hyojin Kim, Tae‐Bin Won
    International Forum of Allergy & Rhinology.2024; 14(12): 1882.     CrossRef
  • Neoadjuvant Capecitabine in Operable HPV‐Negative Head and Neck Cancer: Fortuitous Findings in a Resource Constrained Setting
    Marco A. Mascarella, Keith Richardson, Alex Mlynarek, Michael P. Hier, Derin Caglar, Livia Florianova, Marc Philippe Pusztaszeri, Khalil Sultanem, Nader Sadeghi, Nathaniel Bouganim, Khashayar Esfahani
    Otolaryngology–Head and Neck Surgery.2024; 171(6): 1773.     CrossRef
  • Outcomes of Neoadjuvant Chemotherapy in Locally Advanced Oral Cancers: A Retrospective Analytical Study
    Monesha Baskaran, S.M. Azeem Mohiyuddin, G. N. Manjunath, A. Sagayaraj, M. Kouser, Ravindra P Deo, Anil K Sakalecha, Kalyani Raju, Sampath Kumar M.N.
    Cureus.2024;[Epub]     CrossRef
  • Indian clinical practice consensus guidelines for the management of oropharyngeal cancer - Update 2023
    Vanita Noronha, K Govind Babu, HS Darling, Pankaj Chaturvedi, Moni Kuriakose, Praveen Birur, Ashish Kaushal, Abhishek Mahajan, Manish Singhal, Munish Gairola, Sumit Goyal, Vijay M Patil, Vishal Rao, Goura K. Rath, Prabhash Kumar
    Cancer Research, Statistics, and Treatment.2024; 7(Suppl 2): S54.     CrossRef
  • Suppression of TLR signaling by IRAK-1 and -4 dual inhibitor decreases TPF-resistance-induced pro-oncogenic effects in HNSCC
    Humayara Khan, Sachchida Nand Pandey, Abhishek Mishra, Ratika Srivastava
    3 Biotech.2023;[Epub]     CrossRef
  • Induction Therapy for Locally Advanced Head and Neck Squamous Cell Carcinoma
    Shuwen Zheng, Yumei Feng, Chan Li, Jie Zhang, Ke Xie
    Oncology and Therapy.2023; 11(2): 185.     CrossRef
  • Induction chemotherapy in locally advanced head and neck cancers, is there a best choice?
    Hoda Mahdavi
    Critical Reviews in Oncology/Hematology.2023; 186: 103986.     CrossRef
  • Protective Effect of Electroacupuncture on Chemotherapy-Induced Salivary Gland Hypofunction in a Mouse Model
    Thanh-Hien Vu Nguyen, Kuo-Chou Chiu, Yin-Hwa Shih, Chung-Ji Liu, Tran Van Bao Quach, Shih-Min Hsia, Yi-Hung Chen, Tzong-Ming Shieh
    International Journal of Molecular Sciences.2023; 24(14): 11654.     CrossRef
  • Induction Chemotherapy as a Prognostication Index and Guidance for Treatment of Locally Advanced Head and Neck Squamous Cell Carcinoma: The Concept of Chemo-Selection (KCSG HN13-01)
    Yun-Gyoo Lee, Eun Joo Kang, Bhumsuk Keam, Jin-Hyuk Choi, Jin-Soo Kim, Keon Uk Park, Kyoung Eun Lee, Hyo Jung Kim, Keun-Wook Lee, Min Kyoung Kim, Hee Kyung Ahn, Seong Hoon Shin, Hye Ryun Kim, Sung-Bae Kim, Hwan Jung Yun
    Cancer Research and Treatment.2022; 54(1): 109.     CrossRef
  • The role of induction chemotherapy in patients with locally advanced head and neck squamous cell carcinoma: A nationwide population-based matched study
    Meng-Che Hsieh, Chih-Chun Wang, Chuan-Chien Yang, Ching-Feng Lien, Chien-Chung Wang, Yu-Chen Shih, Shyh-An Yeh, Tzer-Zen Hwang
    Oral Oncology.2022; 128: 105848.     CrossRef
  • SEOM clinical guidelines for the treatment of head and neck cancer (2020)
    R. Mesia, L. Iglesias, J. Lambea, J. Martínez-Trufero, A. Soria, M. Taberna, J. Trigo, M. Chaves, A. García-Castaño, J. Cruz
    Clinical and Translational Oncology.2021; 23(5): 913.     CrossRef
  • EHF suppresses cancer progression by inhibiting ETS1-mediated ZEB expression
    Kaname Sakamoto, Kaori Endo, Kei Sakamoto, Kou Kayamori, Shogo Ehata, Jiro Ichikawa, Takashi Ando, Ryosuke Nakamura, Yujiro Kimura, Kunio Yoshizawa, Keisuke Masuyama, Tomoyuki Kawataki, Kunio Miyake, Hiroki Ishii, Tomonori Kawasaki, Keiji Miyazawa, Masao
    Oncogenesis.2021;[Epub]     CrossRef
  • Sequential chemotherapy regimen of induction with panitumumab and paclitaxel followed by radiotherapy and panitumumab in patients with locally advanced head and neck cancer unfit for platinum derivatives. The phase II, PANTERA/TTCC-2010-06 study
    J. Martínez-Trufero, A. Lozano Borbalas, I. Pajares Bernad, M. Taberna Sanz, E. Ortega Izquierdo, B. Cirauqui Cirauqui, J. Rubió-Casadevall, M. Plana Serrahima, J.M. Ponce Ortega, I. Planas Toledano, J. Caballero, J. Marruecos Querol, L. Iglesias Docampo,
    Clinical and Translational Oncology.2021; 23(8): 1666.     CrossRef
  • Divergent Roles of Induction Chemotherapy in Patients with Unresectable Locally Advanced Head and Neck Squamous Cell Carcinoma: A Population-Based Matched Cohort Study
    Meng-Che Hsieh, Tzer-Zen Hwang, Chih-Chun Wang, Chuan-Chien Yang, Ching-Feng Lien, Chien-Chung Wang, Yu-Chen Shih, Wei-Ching Liu, Kun-Ming Rau
    SSRN Electronic Journal .2021;[Epub]     CrossRef
  • Statin in combination with cisplatin makes favorable tumor-immune microenvironment for immunotherapy of head and neck squamous cell carcinoma
    Minsu Kwon, Gi-Hoon Nam, Hanul Jung, Seong A Kim, Seohyun Kim, Yeonju Choi, Yoon Se Lee, Hyo Jung Cho, In-San Kim
    Cancer Letters.2021; 522: 198.     CrossRef
  • The Role of Genetic Pathways in the Development of Chemoradiation Resistance in Nasopharyngeal Carcinoma (NPC) Patients
    Norhafiza Mat Lazim, Che Ismail Che Lah, Wan Khairunnisa Wan Juhari, Sarina Sulong, Bin Alwi Zilfalil, Baharudin Abdullah
    Genes.2021; 12(11): 1835.     CrossRef
  • Indian clinical practice consensus guidelines for the management of oropharyngeal cancer
    Kumar Prabhash, Govind Babu, Pankaj Chaturvedi, Moni Kuriakose, Praveen Birur, AnilK Anand, Ashish Kaushal, Abhishek Mahajan, Judita Syiemlieh, Manish Singhal, Munish Gairola, Prakash Ramachandra, Sumit Goyal, Subashini John, Rohit Nayyar, VijayM Patil, V
    Indian Journal of Cancer.2020; 57(5): 12.     CrossRef
  • Locally advanced oral tongue cancer: Is organ preservation a safe option in resource-limited high-volume setting?
    Muntazir Hussain, Muhammad Faisal, Muhammad Abu Bakar, Tahir Muhammad, Saman Qadeer, Sameen Mohtasham, Raza Hussain, Arif Jamshed
    Annals of Maxillofacial Surgery.2020; 10(1): 158.     CrossRef
  • Present and Future of De-intensification Strategies in the Treatment of Oropharyngeal Carcinoma
    Armando De Virgilio, Andrea Costantino, Giuseppe Mercante, Gerardo Petruzzi, Daniela Sebastiani, Ciro Franzese, Marta Scorsetti, Raul Pellini, Luca Malvezzi, Giuseppe Spriano
    Current Oncology Reports.2020;[Epub]     CrossRef
  • Treatment strategy and outcomes in locally advanced head and neck squamous cell carcinoma: a nationwide retrospective cohort study (KCSG HN13–01)
    Yun-Gyoo Lee, Eun Joo Kang, Bhumsuk Keam, Jin-Hyuk Choi, Jin-Soo Kim, Keon Uk Park, Kyoung Eun Lee, Jung Hye Kwon, Keun-Wook Lee, Min Kyoung Kim, Hee Kyung Ahn, Seong Hoon Shin, Hye Ryun Kim, Sung-Bae Kim, Hwan Jung Yun
    BMC Cancer.2020;[Epub]     CrossRef
  • Local immune parameters as potential predictive markers in head and neck squamous cell carcinoma patients receiving induction chemotherapy and cetuximab
    Andrea Ladányi, Bence Kapuvári, Eszter Papp, Erika Tóth, József Lövey, Katalin Horváth, Mária Gődény, Éva Remenár
    Head & Neck.2019; 41(5): 1237.     CrossRef
  • Das Ende der TPF-Induktion bei lokoregionär fortgeschrittenen HNO-Karzinomen? Induktionschemotherapie gefolgt von Cetuximab und Bestrahlung nicht effektiver als simultane Radiochemotherapie
    R. M. Hermann, H. Christiansen
    Strahlentherapie und Onkologie.2019; 195(3): 281.     CrossRef
  • A Multicenter Phase II Trial of Docetaxel, Cisplatin, and Cetuximab (TPEx) Followed by Cetuximab and Concurrent Radiotherapy for Patients With Local Advanced Squamous Cell Carcinoma of the Head and Neck (CSPOR HN01: ECRIPS Study)
    Sadamoto Zenda, Yosuke Ota, Naomi Kiyota, Susumu Okano, Masato Fujii, Morimasa Kitamura, Shunji Takahashi, Tsutomu Ueda, Nobuya Monden, Takeharu Yamanaka, Makoto Tahara
    Frontiers in Oncology.2019;[Epub]     CrossRef
  • Induction chemotherapy in head and neck cancers: Results and controversies
    Max Gau, Andy Karabajakian, Thibaut Reverdy, Eve-Marie Neidhardt, Jérôme Fayette
    Oral Oncology.2019; 95: 164.     CrossRef
  • CTX-Induktion gefolgt von Cetuximab und Bestrahlung nicht effektiver als simultane RCT
    Hans Christiansen, Robert M. Hermann
    InFo Hämatologie + Onkologie.2019; 22(7-8): 27.     CrossRef
  • A Phase II Study of Genexol-PM and Cisplatin as Induction Chemotherapy in Locally Advanced Head and Neck Squamous Cell Carcinoma
    Bhumsuk Keam, Keun-Wook Lee, Se-Hoon Lee, Jin-Soo Kim, Jin Ho Kim, Hong-Gyun Wu, Keun-Yong Eom, Suzy Kim, Soon-Hyun Ahn, Eun-Jae Chung, Seong Keun Kwon, Woo-Jin Jeong, Young Ho Jung, Ji-Won Kim, Dae Seog Heo
    The Oncologist.2019; 24(6): 751.     CrossRef
  • Platelet-lymphocyte and neutrophil-lymphocyte ratios
    Yu-Hsi Liu, Yaoh-Shiang Lin
    Journal of the Chinese Medical Association.2019; 82(11): 849.     CrossRef
  • Administration of nimotuzumab combined with cisplatin plus 5-fluorouracil as induction therapy improves treatment response and tolerance in patients with locally advanced nasopharyngeal carcinoma receiving concurrent radiochemotherapy: a multicenter rando
    Ying Lu, Dagui Chen, Jinhui Liang, Jianquan Gao, Zhanxiong Luo, Rensheng Wang, Wenqi Liu, Changjie Huang, Xuejian Ning, Meilian Liu, Haixin Huang
    BMC Cancer.2019;[Epub]     CrossRef
  • SEOM clinical guidelines for the treatment of head and neck cancer (2017)
    L. C. Iglesias Docampo, V. Arrazubi Arrula, N. Baste Rotllan, A. Carral Maseda, B. Cirauqui Cirauqui, Y. Escobar, J. J. Lambea Sorrosal, M. Pastor Borgoñón, A. Rueda, J. J. Cruz Hernández
    Clinical and Translational Oncology.2018; 20(1): 75.     CrossRef
  • Radiotherapy for locally advanced resectable T3–T4 laryngeal cancer—does laryngeal preservation strategy compromise survival?
    Hideya Yamazaki, Gen Suzuki, Satoaki Nakamura, Shigeru Hirano, Ken Yoshida, Koji Konishi, Teruki Teshima, Kazuhiko Ogawa
    Journal of Radiation Research.2018; 59(1): 77.     CrossRef
  • Any place left for induction chemotherapy for locally advanced head and neck squamous cell carcinoma?
    Mickaël Burgy, Julie Leblanc, Christian Borel
    Anti-Cancer Drugs.2018; 29(4): 287.     CrossRef
  • A retrospective study of treatment for curative synchronous double primary cancers of the head and neck and the esophagus
    Tabito Okamoto, Chikatoshi Katada, Shouko Komori, Keishi Yamashita, Shunsuke Miyamoto, Koichi Kano, Yutomo Seino, Hiroshi Hosono, Hiroki Matsuba, Hiromitsu Moriya, Mitsuhiro Sugawara, Mizutomo Azuma, Hiromichi Ishiyama, Satoshi Tanabe, Kazushige Hayakawa,
    Auris Nasus Larynx.2018; 45(5): 1053.     CrossRef
  • 5-Fluorouracil induces inflammation and oxidative stress in the major salivary glands affecting salivary flow and saliva composition
    Luana E. Bomfin, Cíntia M. Braga, Thais A. Oliveira, Conceição S. Martins, Danielle A. Foschetti, Ana A.Q.A. Santos, Deiziane V.S. Costa, Renata F.C. Leitão, Gerly A.C. Brito
    Biochemical Pharmacology.2017;[Epub]     CrossRef
  • Clinical and Histologic Predictive Factors of Response to Induction Chemotherapy in Head and Neck Squamous Cell Carcinoma
    Georgia Karpathiou, Jean-Baptiste Giroult, Fabien Forest, Pierre Fournel, Alessandra Monaya, Marios Froudarakis, Jean Marc Dumollard, Jean Michel Prades, Marie Gavid, Michel Peoc'h
    American Journal of Clinical Pathology.2016; 146(5): 546.     CrossRef
  • 14,303 View
  • 373 Download
  • 37 Web of Science
  • 40 Crossref
Close layer
Synergistic Effect of Sulindac and Simvastatin on Apoptosis in Lung Cancer A549 Cells through AKT-Dependent Downregulation of Survivin
Young-Suk Kim, Chang-Hwan Seol, Jae-Wan Jung, Su-Jin Oh, Ki-Eun Hwang, Hwi-Jung Kim, Eun-Taik Jeong, Hak-Ryul Kim
Cancer Res Treat. 2015;47(1):90-100.   Published online October 27, 2014
DOI: https://doi.org/10.4143/crt.2013.194
AbstractAbstract PDFPubReaderePub
Purpose
Non-steroidal anti-inflammatory drugs (NSAIDs) and statins are potential chemopreventive or chemotherapeutic agents. The mechanism underlying the deregulation of survivin by NSAIDs and statins in human non-small cell lung cancer cells has not been elucidated. In this study, we investigated the synergistic interaction of sulindac and simvastatin in lung cancer A549 cells.
Materials and Methods
Cell viability was measured by an MTT assay, while the expression of apoptotic markers, AKT, and survivin in response to sulindac and simvastatin was examined by Western blotting. DNA fragmentation by apoptosis was analyzed by flow cytometry in A549 cells. Reactive oxygen species (ROS) generation was measured by flow cytometry using H2DCFDA and MitoSOX Red, and the effects of pretreatment with N-acetylcysteine were tested. The effects of AKT on survivin expression in sulindac- and simvastatin-treated cells were assessed. Survivin was knocked down or overexpressed to determine its role in apoptosis induced by sulindac and simvastatin.
Results
Sulindac and simvastatin synergistically augmented apoptotic activity and intracellular ROS production in A549 cells. Inhibition of AKT by siRNA or LY294002 inhibited survivin, while AKT overexpression markedly increased survivin expression, even in the presence of sulindac and simvastatin. Moreover, survivin siRNA enhanced sulindac- and simvastatininduced apoptosis. In contrast, survivin upregulation protected against sulindac- and simvastatin-induced apoptosis.
Conclusion
Combined treatment with sulindac and simvastatin augmented their apoptotic potential in lung cancer cells through AKT signaling-dependent downregulation of survivin. These results indicate that sulindac and simvastatin may be clinically promising therapies for the prevention of lung cancer.

Citations

Citations to this article as recorded by  
  • Regulatory effects of statins on Akt signaling for prevention of cancers
    Fatemeh Sadat Hosseini, Abdolreza Ahmadi, Prashant Kesharwani, Hossein Hosseini, Amirhossein Sahebkar
    Cellular Signalling.2024; 120: 111213.     CrossRef
  • Sulindac exhibits anti-proliferative and anti-invasive effects in uterine serous carcinoma cells
    Shuning Chen, Weimin Kong, Xiaochang Shen, Boer Deng, Jennifer Haag, Nikita Sinha, Catherine John, Wenchuan Sun, Chunxiao Zhou, Victoria L. Bae-Jump
    Journal of Cancer Research and Clinical Oncology.2024;[Epub]     CrossRef
  • BAPST. A Combo of Common Use Drugs as Metabolic Therapy for Cancer: A Theoretical Proposal
    Adriana Romo-Perez, Guadalupe Dominguez-Gomez, Alma Chavez-Blanco, Lucia Taja-Chayeb, Aurora Gonzalez-Fierro, Elisa Garcia-Martinez, Jose Correa-Basurto, Alfonso Duenas-Gonzalez
    Current Molecular Pharmacology.2022; 15(6): 815.     CrossRef
  • Cholesterol-Lowering Drugs on Akt Signaling for Prevention of Tumorigenesis
    Navneet Kumar, Chandi C. Mandal
    Frontiers in Genetics.2021;[Epub]     CrossRef
  • Small molecules regulating reactive oxygen species homeostasis for cancer therapy
    Junmin Zhang, Dongzhu Duan, Zi‐Long Song, Tianyu Liu, Yanan Hou, Jianguo Fang
    Medicinal Research Reviews.2021; 41(1): 342.     CrossRef
  • Lanthanum(III) and neodymium(III) complexes with anti-inflammatory drug sulindac: Synthesis, characterization, thermal investigation using coupled techniques TG-FTIR, and in vitro biological studies
    Renan B. Guerra, Thais Fernanda de Campos Fraga-Silva, Julia Aguiar, Paula B. Oshiro, Bruno B.C. Holanda, James Venturini, Gilbert Bannach
    Inorganica Chimica Acta.2020; 503: 119408.     CrossRef
  • A remarkable in vitro cytotoxic, cell cycle arresting and proapoptotic characteristics of low-dose mixed micellar simvastatin combined with alendronate sodium
    Sandip A. Bandgar, Namdeo R. Jadhav, Arehalli S. Manjappa
    Drug Delivery and Translational Research.2020; 10(4): 1122.     CrossRef
  • Repositioning of drugs for intervention in tumor progression and metastasis: Old drugs for new targets
    Giridhar Mudduluru, Wolfgang Walther, Dennis Kobelt, Mathias Dahlmann, Christoph Treese, Yehuda G. Assaraf, Ulrike Stein
    Drug Resistance Updates.2016; 26: 10.     CrossRef
  • Simvastatin Reduces Cancerogenic Potential of Renal Cancer Cells via Geranylgeranyl Pyrophosphate and Mevalonate Pathway
    Mathias Woschek, Niels Kneip, Katrin Jurida, Ingo Marzi, Borna Relja
    Nutrition and Cancer.2016; 68(3): 420.     CrossRef
  • Celecoxib and sulindac inhibit TGF-β1-induced epithelial-mesenchymal transition and suppress lung cancer migration and invasion via downregulation of sirtuin 1
    Byong-Ki Cha, Young-Suk Kim, Ki-Eun Hwang, Kyung-Hwa Cho, Seon-Hee Oh, Byoung-Ryun Kim, Hong-Young Jun, Kwon-Ha Yoon, Eun-Taik Jeong, Hak-Ryul Kim
    Oncotarget.2016; 7(35): 57213.     CrossRef
  • Ultra-structure changes and survivin expression in uterine fibroids after radiofrequency ablation
    Shan-rong Shu, Xin Luo, Wen-Xia Song, Pei-Wen Chen
    International Journal of Hyperthermia.2015; 31(8): 896.     CrossRef
  • 15,498 View
  • 127 Download
  • 15 Web of Science
  • 11 Crossref
Close layer
Case Report
Pseudoaneurysm Due to Squamous Cell Carcinoma of the Lung: Two Cases of Spontaneous Resolution after Chemotherapy
So-Young Kim, Hak-Ryul Kim, Jung-Sub Song, Ki-Eun Hwang, Jeong-Hyun Shin, Seoung-Nam Shin, Dong Kim, Seong-Hoon Park, Sei-Hoon Yang, Eun-Taik Jeong
Cancer Res Treat. 2009;41(4):237-240.   Published online December 31, 2009
DOI: https://doi.org/10.4143/crt.2009.41.4.237
AbstractAbstract PDFPubReaderePub

Pseudoaneurysm due to cancer is uncommon generally and is extremely rare in lung cancer. We report two cases of false aneurysms due to lung cancer that spontaneously regressed upon chemotherapy without intervention. Both patients had squamous cell carcinoma of the lung and the diagnosis of a pseudoaneurysm was made using computed tomography. There was no evidence of severe bronchial hemorrhage and the psuedoaneurysms were small and well-encased. Chemotherapy was performed and the pseudoaneurysms resolved.

Citations

Citations to this article as recorded by  
  • Left Pulmonary Artery Aneurysm Secondary to Metastatic Lung Sarcoma: A Case Report
    Muhammad Abdullah Javed, Kaleem S Ahmed, Mohammad Bin Pervez, Saira Fatima, Saulat Hasnain Fatimi
    Cureus.2023;[Epub]     CrossRef
  • Fatal rupture of pulmonary artery pseudoaneurysm after thoracic radiation therapy against lung squamous cell carcinoma: A case report and literature review
    Yosuke Fukuda, Tetsuya Homma, Tomoki Uno, Yasunori Murata, Shintaro Suzuki, Eisuke Shiozawa, Masafumi Takimoto, Hironori Sagara
    Clinical Case Reports.2021; 9(2): 737.     CrossRef
  • Embolisation of large pulmonary artery pseudoaneurysm with conservative treatment of delayed coil extrusion
    S Elangovan, CW Too
    Singapore Medical Journal.2020; 61(3): 162.     CrossRef
  • An unusual presentation of pulmonary artery sarcoma: Several pseudoaneurysms with massive hemoptysis
    Oguzhan Yildiz, Emre Unal, Turkmen Turan Ciftci, Devrim Akinci, Orhan Macit Ariyurek
    The American Journal of Emergency Medicine.2020; 38(9): 1966.e1.     CrossRef
  • Pseudoaneurysm of the aortic arch
    Yuan-Qiang Lu, Feng Yao, An-Dong Shang, Jian Pan
    Medicine.2016; 95(31): e4457.     CrossRef
  • Pseudoaneurysm of pulmonary artery: rare complication of systemic chemotherapy
    Shivani Garg, Gentry King, Gabor Varadi
    Clinical Case Reports.2015; 3(10): 845.     CrossRef
  • Aneurysms and Pseudoaneurysms of the Pulmonary Vasculature
    Carlos S. Restrepo, Aimee P. Carswell
    Seminars in Ultrasound, CT and MRI.2012; 33(6): 552.     CrossRef
  • A Case of Pseudoaneurysm Developed during Intensive Treatment of Status Asthmaticus - A Case Report -
    Dong Kim, Jeong-Hyun Shin, Dong-Hyo No, Hyeong-Cheol Cheong, Kyung-Hwa Cho, Ki-Eun Hwang, Hwi-Jung Kim, Eun-Taik Jeong, Hak-Ryul Kim
    The Korean Journal of Critical Care Medicine.2010; 25(4): 241.     CrossRef
  • 8,829 View
  • 69 Download
  • 8 Crossref
Close layer
Original Articles
Arsenic Trioxide Induces Apoptosis of HL-60 Cells via Activation of Intrinsic Caspase Protease with Mitochondrial Dysfunction
Byung Hak Jung, Channy Park, Hak Ryul Kim, Moo Rim Park
Cancer Res Treat. 2002;34(4):308-315.   Published online August 31, 2002
DOI: https://doi.org/10.4143/crt.2002.34.4.308
AbstractAbstract PDF
Arsenic trioxide (As2O3) was introduced into the treatment of refractory or relapsed acute promyelocytic leukemia and showed a striking effectiveness in China and United States multicenter study. However, the mechanistic basis for the carcinogenic or therapeutic effects of arsenics is still poorly understood. So, this study is performed to determine whether As2O3 induces apoptosis through intrinsic caspase cascades in acute promyelocytic leukemia HL-60 cells.
MATERIALS AND METHODS
HL-60 cells were treated with As2O3 to investigate apoptosis through signaling of caspase cascades and mitochondrial dysfunction.
RESULTS
As2O3 (>0.5 uM) decreased the viability of HL-60 cells in a dose-dependent manner, which was revealed as apoptosis shown chromatin condensation and ladder pattern DNA fragmentation. As2O3 increased the catalytic activity of caspase family cysteine proteases including caspase-3 and -9 proteases. Consistently, PARP, an intracellular biosubstrate of caspase-3 protease, was cleaved from 116 kDa to 85 kDa fragments. It also induced the change of mitochondrial membrane potential. Morever, As2O3 resulted in the increase of Bak.
CONCLUSION
These data suggest that As2O3 induces apoptosis of HL-60 cells through activation of intrinsic caspase protease with mitochondrial dysfunction.

Citations

Citations to this article as recorded by  
  • The Time‐Dependent Serial Gene Response to Zeocin Treatment Involves Caspase‐Dependent Apoptosis in HeLa Cells
    Jooyeon Hwang, Young‐Youl Kim, Sungjin Huh, Junghee Shim, Chan Park, Kuchan Kimm, Dong Kug Choi, Tae‐Kyu Park, Soonhag Kim
    Microbiology and Immunology.2005; 49(4): 331.     CrossRef
  • 3,522 View
  • 21 Download
  • 1 Crossref
Close layer
The Expression of a Novel 90 kDa Stress Protein in Human Malignant Neoplasms
Hong Rae Cho, Gyu Yeol Kim, Chan Jin Park, Byung Kyun Ko, Chang Woo Nam, Sung Sook Kim, Hae Who Park, Do Ha Kim, Sung Ryul Kim, Jeong Woo Park, Won Joon Yoon, Jeong Min Park, Seung Ju Cha, Wha Ja Cho, Dae Hwa Choi
J Korean Cancer Assoc. 1999;31(4):793-801.
AbstractAbstract PDF
PURPOSE
When cells are subjected to stressful stimuli such as, heat shock, toxic metal, nutrient deprivation, and metabolic disruption, they increase production of specific stress proteins that buffer them from harm. We reported that the expression of a navel 90 kDa cellular protein was increased by the infection of a fish rhabdovirus and heat shock in a fish cell. This new 90 kDa protein is not expressed in normal animal tissues but is highly induced in progressively transforming tissues or cells. That gives us some ideas tl at it is possible for this stress protein to be expressed in specific human cancer tissues.
MATERIALS AND METHODS
Commercialized checkerboard multi-tumor block (DAKO Co. Carpinteria, CA) was used for immunohistochemical analysis. The samples of human gastric cancer, colon cancer and breast cancer tissues were evaluated by Western blot and Northern blot for overexpression of the novel 90 kDa stress protein. Sera of those patients were analyzed by ELISA for the presence of antibody against the novel 90 kDa stress protein.
RESULTS
Immunohistochemical staining of human tumor tissue blocks showed significant immunostaining of novel 90 kDa stress protein in carcinomas such as colon cancer, breast cancer and stomach cancer but no apparent immunostaining in sarcomas. Coinciding with the immunohistochemical result, Western blotting and Northern blotting analyses indicate that the expression of the novel 90 kDa stress protein was increased in carcinomas. In addition, the antibody titer against the novel 90 kDa stress protein was found to be elevated in the sera of cancer patients.
CONCLUSIONS
The novel 90 kDa stress protein gene expression was elevated in carcinomas such as gastric cancer, breast cancer and colon cancer. These findings suggest that this new stress protein can be used as a tumor marker and may function as a chaperone in tumor growth.
  • 2,899 View
  • 15 Download
Close layer
Acinar Cell Carcinoma in a Pancreas : Report of a recurrent case
Eun Sook Lee, Ki Hoon Jung, Nam Ryul Kim, Seon Hahn Kim, Sae Min Kim, Chul Hwan Kim
J Korean Cancer Assoc. 1996;28(4):782-787.
AbstractAbstract PDF
Acinar cell carcinoma of the pancreas is a rare neoplasm arising from the exocrine cells of the pancreas, comprising no more than 1 to 2% of all pancreatic cancers. CT appearence of pancreatic acinar carcinoma has been described as a sharply circumscribed mass with central necrosis. We report a case of recurrent acinar cell carcinoma of the pancreas in a 41-year-old man who had distal pancreatectomy three years ago for primary acinar cell carcinoma.
  • 2,768 View
  • 19 Download
Close layer

Cancer Res Treat : Cancer Research and Treatment
Close layer
TOP